This $215,546 Project Grant was awarded by the National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH), under the Minority Health and Health Disparities Research (CFDA 93.307) program. The project aims to evaluate the equity impact and cost-effectiveness of three real-world lung cancer screening strategies: the U.S. Preventive Services Task Force (USPSTF) guidelines, the American Cancer Society (ACS) guidelines, and a screening...
This Project Grant award, in the amount of $269,942, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award aims to develop and pilot test a community health worker (CHW) intervention to improve lung cancer screening (LCS) uptake and address disparities in LCS among Black and Hispanic communities served by community health centers. The key products and services to be delivered include: 1) Jointly...
This federal Project Grant award of $932,740.00, awarded on September 16, 2024 by the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research), supports a research study by the Morehouse School of Medicine to determine racial disparities in lung cancer treatment and survival outcomes for Black non-small cell lung cancer (NSCLC) patients compared to White NSCLC patients. The study aims to 1) document any differences in receipt of...
This Project Grant award of $1,958,708.00 from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify the burden and impact of false-positive results from lung cancer screening (LCS) using low-dose computed tomography. The primary objectives are to: 1) Identify attitudes, knowledge, and experiences with false-positive LCS results among patients and clinicians; 2) Determine patient-, exam-, radiologist-, and facility-level...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $368,288 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate molecular mechanisms underlying disparities in lung cancer outcomes experienced by patients of African ancestry. The key objectives are to: 1) determine how EGFR signaling differs based on patient genetic ancestry, 2) quantify the interplay between EGFR...
This $602,315 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research to validate a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test lung cancer prevention agents. The key objectives are to: 1) Define the human relevance of the in vivo NTCU/smoke mouse model of lung SCC premalignancy, 2) Validate an ex vivo precision cut lung slice approach to screening new prevention...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $968,999.00 to the University of North Carolina at Chapel Hill to conduct research titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The overarching goal is to optimize survivorship of early-stage non-small cell lung cancer patients by incorporating a risk-based surveillance strategy that...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will support a hybrid effectiveness-implementation trial to evaluate a novel harm reduction approach for oncology outpatients who smoke but refuse traditional tobacco treatment. The $619,175 award, effective December 1, 2024, will be used by the Medical University of South Carolina to directly compare rates of switching from cigarettes to e-cigarettes...
The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
This Project Grant award, with Federal Grant Award ID R01CA296150, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The award of $667,828 supports a research project to adapt and implement the Ask-Advise-Connect (AAC) tobacco cessation model in community-based food pantry settings, in order to enhance the reach and effectiveness of tobacco quitline services for socioeconomically disadvantaged populations....
This Project Grant award of $801,832 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports a multilevel integrated intervention to improve low-dose computed tomography (LDCT) lung cancer screening and smoking cessation among African Americans. The primary objectives are to investigate smokers' and providers' attitudes, knowledge, and experiences with the expanded 2021 USPSTF lung cancer screening recommendations, compare the effectiveness of the multilevel integrated intervention versus usual care on smoking abstinence rates and LDCT uptake, and explore barriers and facilitators influencing these outcomes. The award, effective from September 23, 2024 to June 30, 2025, aims to reduce lung cancer disparities and the burden among African American smokers through a culturally relevant, community-engaged, and sustainable program integrating lung cancer screening and smoking cessation.